BETHESDA, MD--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced results of its phase 2b dose-ranging study of AMITIZA® (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC), conducted in Japan. The study demonstrated a statistically significant increase in mean change in spontaneous bowel movements (SBM) from baseline after one week on treatment (p<0.0001), the study’s primary endpoint, for patients taking AMITIZA 24 micrograms twice daily versus placebo.
